OUTCOMES FOLLOWING PRENATAL EXPOSURE TO ANTIDEPRESSANTS

产前接触抗抑郁药后的结果

• 批准号: 2449651
• 负责人: GREGORY G SIMON
• 金额: $ 7.33万
• 依托单位: KAISER FOUNDATION HEALTH PLAN OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-03-01 至 2000-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2449651
• 关键词: age at pregnancy; antidepressants; child behavior; child physical development; clinical research; congenital disorders; disease /disorder proneness /risk; embryo /fetus drug adverse effect; human data; language development; medical records; outcomes research; premature labor; prenatal care; prenatal growth disorder; prenatal stress; statistics /biometry

DESCRIPTION (Applicant's Abstract): Among women of childbearing age, depression is among the most common chronic illnesses and antidepressant drugs are among the most common long-teem medications. For women with depressive illness, available data give unclear guidance about continuing antidepressant drug use during pregnancy. We propose a population- based study of birth outcomes among a cohort of children exposed to antidepressant drugs in utero and a comparison co hon of unexposed children. We will use computerized pharmacy data to assess antidepressant exposure. Potential adverse effects (e.g. congenital malformations, developmental delay) will be identified using newborn examination records, outpatient pediatric records, and computerized visit data. Potential confounding factors (e.g. other prenatal exposures) will be assessed from maternal records Exposed and unexposed cohorts will be matched for maternal age and maternal history of depression treatment. Outcomes of exposed and unexposed children will be examined to test whether prenatal antidepressant exposure is associated with an increased likelihood of: Delivery prior to 37 weeks; Intra-uterine growth retardation; Poor neonatal adaptation; Specific congenital malformations; Clinically significant delay in motor language or social development These data should help to clarify the risks associated with continued use of antidepressant drugs during pregnancy and conception. Important strengths of the proposal include selection of a population-based sample of exposed children and use of a comparison group matched for maternal history of depression treatment.

描述(申请人摘要)：在育龄妇女中， 抑郁症是最常见的慢性病之一，也是抗抑郁药 药物是最常见的长效药物之一。对于女性来说， 抑郁症，现有数据给出了关于继续的不明确指导 妊娠期使用抗抑郁药。我们提出了以人口为基础的 一组接触抗抑郁药物的儿童的出生结局研究 宫内药物和未接触过的儿童的比较。我们将使用 计算机化的药房数据以评估抗抑郁药的暴露情况。潜力 不良影响(如先天畸形、发育迟缓) 通过新生儿检查记录，门诊儿科记录， 和计算机化的访问数据。潜在的混杂因素(例如其他 产前暴露)将根据暴露的孕产妇记录进行评估 未暴露的队列将与母亲的年龄和母亲的病史相匹配 抑郁症治疗。接触过和未接触过的儿童的结果将是 接受检查以测试产前接触抗抑郁药是否与 更高的可能性：在37周前分娩；宫内 生长迟缓；新生儿适应不良；特殊先天 畸形；临床上有明显的运动语言或社交迟缓 发展 这些数据应有助于澄清与继续使用 孕期和受孕期的抗抑郁药物。重要优势 该建议包括以总体为基础的暴露样本的选择 与母体病史相匹配的儿童和对照组的使用 抑郁症治疗。